GL1X · GenesisL1 explorer

Research workbench

The escherichia COLI lytic transglycosylase SLT35 in complex with two murodipeptides (glcnac-murnac-L-ala-D-glu)

Analyse The escherichia COLI lytic transglycosylase SLT35 in complex with two… in the GL1X research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides, crosslinks and neighbours on the 3D structure.

PDB
1D0K
Type
protein
Length
318 residues
Chains
1
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
35KD soluble lytic transglycosylase
UniProt
P41052
Ligands
AMU, NAG, CA
Pockets
2 · best druggability 0.64

Structure

x-ray diffraction · 1 distinct chain · 51% helix, 11% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
A35KD soluble lytic transglycosylaseprotein31851% helix, 11% strandP41052

Ligands and binding sites

  • AMU · N-acetyl-beta-muramic acid · ligand · 2 copies · chains A
  • NAG · 2-acetamido-2-deoxy-beta-D-glucopyranose · sugar · 2 copies · chains A
  • CA · Calcium ion · metal · chains A
  • GOL · Glycerol · additive · chains A

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

2 pockets found on a 1 Å grid, 1 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
15120.640.7642AMU, NAG, GOL
2510.310.7713empty

Modifications

Observed in the structure: 2 covalent, 2 d-amino (covalent ligand, D-amino acid).

Compared structures

  • 1D0K · The escherichia COLI lytic transglycosylase SLT35 in complex with two murodipeptides… · the same entry in another collection · chain A against A, TM-score 1.00
  • P41052 · AlphaFold monomer V2.0 prediction for membrane-bound lytic murein transglycosylase B… · a predicted model of the same protein · chain A against A, TM-score 0.94

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.